Rocket Pharmaceuticals (RCKT) News Today $6.27 -0.29 (-4.42%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.28 +0.01 (+0.08%) As of 05/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Woodline Partners LP boosted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 8.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 652,421 shares of the biotechnologMay 25 at 4:41 AM | marketbeat.comToronto Dominion Bank Purchases Shares of 1,100,000 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Toronto Dominion Bank purchased a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,100,000 shares of the biotechnologyMay 22 at 5:05 AM | marketbeat.com271,659 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Soleus Capital Management L.P.Soleus Capital Management L.P. bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 271,659 shares of the biotechnology company's stock, valued at approximately $3,415,000. Soleus CapMay 21, 2025 | marketbeat.comNorthern Trust Corp Has $8.34 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Northern Trust Corp increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 14.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 663,152 shares of the biotechnology comMay 21, 2025 | marketbeat.comTema Etfs LLC Invests $1.14 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Tema Etfs LLC purchased a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 90,985 shares of the biotechnology company's stock, valued at appMay 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 1,521,727 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Point72 Asset Management L.P. increased its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 3,163.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,569,823 shares of the biotechnoMay 20, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Raised by BNP Paribas Financial MarketsBNP Paribas Financial Markets grew its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 302.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 158,439 shares of the biotechnolMay 20, 2025 | marketbeat.comSuvretta Capital Management LLC Invests $32.27 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Suvretta Capital Management LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,566,951 shares of the biotechnology company's stocMay 19, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Earns Outperform Rating from WedbushMay 19, 2025 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Sphera Funds Management LTD.Sphera Funds Management LTD. lifted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 17.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,792 shares of the biotechnology coMay 18, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $30.00 Price Target at Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comChardan Capital Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 18, 2025 | americanbankingnews.comProsight Management LP Buys 929,337 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Prosight Management LP boosted its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 583.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,088,706 shares of the biotechnologyMay 17, 2025 | marketbeat.comMPM Bioimpact LLC Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)MPM Bioimpact LLC decreased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,020,559 shares of the biotechnology comMay 16, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Estimate for RCKT EarningsRocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Rocket Pharmaceuticals in a report issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the biotechnology company willMay 16, 2025 | marketbeat.comLMR Partners LLP Takes $943,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)LMR Partners LLP bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 75,000 shares of the biotechnology company's stock, valuedMay 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 2,106,699 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Janus Henderson Group PLC boosted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 111.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,004,039 shares of the biotechnology company'May 16, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 7.5% After Analyst DowngradeRocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 7.5% on Analyst DowngradeMay 15, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at ScotiabankScotiabank decreased their price objective on shares of Rocket Pharmaceuticals from $52.00 to $51.00 and set a "sector outperform" rating for the company in a research note on Monday.May 14, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $34.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group decreased their target price on Rocket Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday.May 14, 2025 | marketbeat.comIs Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?May 13, 2025 | insidermonkey.comAlgert Global LLC Invests $504,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Algert Global LLC acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 40,060 shares of the biotechnology company's stock, valued at apprMay 13, 2025 | marketbeat.comRocket Pharmaceuticals price target lowered to $51 from $52 at ScotiabankMay 12, 2025 | msn.comDimensional Fund Advisors LP Has $9.57 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Dimensional Fund Advisors LP cut its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 16.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 760,941 shares of the biotechnology company's stock after selling 15May 12, 2025 | marketbeat.comRocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell TherapyMay 9, 2025 | businesswire.comRocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent ProgressMay 8, 2025 | businesswire.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bamco Inc. NYBamco Inc. NY trimmed its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 91.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,000 shares of the biotechnologyMay 8, 2025 | marketbeat.comAvidity Partners Management LP Boosts Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Avidity Partners Management LP raised its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 40.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,053,300 shares of theMay 6, 2025 | marketbeat.comBaker BROS. Advisors LP Buys Shares of 97,079 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Baker BROS. Advisors LP purchased a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 97,079 shares of the biotecMay 6, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eleven haveMay 5, 2025 | marketbeat.comAcuta Capital Partners LLC Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Acuta Capital Partners LLC lessened its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 29.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 134,500 shares of the biotechnolMay 4, 2025 | marketbeat.comBoxer Capital Management LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Boxer Capital Management LLC purchased a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,466,051 shares of the biotechnology coMay 4, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 59,261 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Price T Rowe Associates Inc. MD reduced its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,148,520 shares of the biotechnologyMay 2, 2025 | marketbeat.comRocket Pharmaceuticals (RCKT) to Release Earnings on MondayRocket Pharmaceuticals (NASDAQ:RCKT) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-rocket-pharmaceuticals-inc-stock/)April 30, 2025 | marketbeat.comRenaissance Technologies LLC Acquires Shares of 218,519 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Renaissance Technologies LLC acquired a new stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 218,519 shares of the biotechnology company's stockApril 27, 2025 | marketbeat.com48,400 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Bought by NatixisNatixis acquired a new stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 48,400 shares of the biotechnology company's stock, valued at approximately $608,000. Natixis owned apprApril 26, 2025 | marketbeat.comMarshall Wace LLP Purchases 446,662 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Marshall Wace LLP raised its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 4,422.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 456,762 shares of the biotechnology company's stock after buyinApril 26, 2025 | marketbeat.comRocket Lab USA takes aim at SpaceX with Neutron RocketApril 25, 2025 | msn.comTickets to Rocket Classic, Detroit's PGA Tour stop, now on saleApril 25, 2025 | detroitnews.comWarriors' Steve Kerr shares disappointment in Rocket's fans chants toward Draymond GreenApril 25, 2025 | msn.comWhy Is Rocket Lab Stock Trading Higher On Thursday?April 24, 2025 | benzinga.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 3.6% - Time to Sell?Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 3.6% - Here's WhyApril 24, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 8.9% - Here's What HappenedRocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 8.9% - Time to Buy?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Avoro Capital Advisors LLC acquired a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,200,000 shares of the biotechnology company's stockApril 23, 2025 | marketbeat.comVoss Capital LP Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Voss Capital LP bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 421,700 shares of the biotechnology company's stock, valued at approximateApril 23, 2025 | marketbeat.comGeode Capital Management LLC Increases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Geode Capital Management LLC grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,752,975 shares of the biotechnology compaApril 21, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Alliancebernstein L.P.Alliancebernstein L.P. reduced its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 74.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,760 shares of the biotechnologyApril 21, 2025 | marketbeat.comWalleye Capital LLC Has $2.77 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Walleye Capital LLC grew its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 59.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 220,142 shares of the biotecApril 20, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 41,024 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)JPMorgan Chase & Co. reduced its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 515,528 shares of the biotechnology company's stock aApril 20, 2025 | marketbeat.comXTX Topco Ltd Has $800,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)XTX Topco Ltd boosted its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 310.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,634 shares of the biotechnology company's stock aApril 19, 2025 | marketbeat.com Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Media Mentions By Week RCKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCKT News Sentiment▼1.270.75▲Average Medical News Sentiment RCKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCKT Articles This Week▼116▲RCKT Articles Average Week Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News Today IMVT News Today IBRX News Today XENE News Today AMRX News Today HCM News Today OGN News Today MIRM News Today APLS News Today ARWR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RCKT) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
